For the Inventor, By the Inventor

Enter assignee name

San Diego, CA, United States of America

Bionomics Inc.

USPTO Granted Patents = 64

CIPO Patents = 4

EPO Patents = 25

Trademarks = 1

Forward Citations = 189

Loading Chart...

Loading Chart...

91 inventors (with patents filed for the assignee):

Bernard Luke Flynn (25 out of 27 patents)

Dharam Paul (16 out of 19 patents)

Jonathan Bayldon Baell (13 out of 28 patents)

4. Gabriel Kremmidiotis (13 out of 13 patents)

5. Andrew John Harvey (12 out of 23 patents)

6. Christopher L Reyes (10 out of 12 patents)

7. Jason Hugh Chaplin (10 out of 11 patents)

8. Peter Chu (9 out of 9 patents)

9. Damian Wojciech Grobelny (9 out of 19 patents)

10. Brad E Sleebs (9 out of 15 patents)

11. Nurul Quazi (8 out of 10 patents)

12. Rajinder Singh (8 out of 11 patents)

13. Chinh Thien Bui (8 out of 12 patents)

14. Samuel Frank Berkovic (8 out of 13 patents)

15. Ian Phillip Street (7 out of 7 patents)

Core Competencies:

Therapeutic Formulations

Cyclic Compounds

Ion Channel Receptors

Checkpoint Inhibitor Therapy

Acute Myeloid Leukemia

Predictive Biomarkers

Humanized Antibodies

Anxiolytic Compounds

Tubulin Polymerisation Inhibitors

Potassium Channel Blockers

Cancer Treatment Protocols

Combination Therapy

64 patents: Sort by Forward Citations

1. 12409140 - Therapeutic formulations and uses thereof (2025-09-09),

2. 12275732 - Cyclic compounds as receptor modulating therapeutics and methods and uses thereof (2025-04-14),

3. 12139473 - Substituted-N-heteroaryl compounds and uses thereof (2024-11-12),

4. 12090146 - Substituted-pyridinyl compounds and uses thereof (2024-09-17),

5. 11884673 - Modulators of ion channel receptors and uses thereof (2024-01-30),

6. 11655304 - Antibody and checkpoint inhibitor combination therapy (2023-05-23),

7. 11478445 - Method for treating acute myeloid leukemia (2022-10-25),

8. 11384085 - Modulators of ion channel receptors and uses thereof (2022-07-12),

9. 10954231 - Anxiolytic compounds (2021-03-23),

10. 10745487 - Method of treating cancer by administering an anti-LGR5 monoclonal antibody (2020-08-18),

11. 10598653 - Methods of blocking cancer stem cell growth (2020-03-24),

12. 10564162 - Predictive biomarkers (2020-02-18),

13. 10520508 - Predictive baseline biomarkers for use of vascular disrupting agents (2019-12-31),

14. 10358500 - Humanized antibodies that bind LGR5 (2019-07-23),

15. 10266529 - Salts, co-crystals, and polymorphs of an anxiolytic compound (2019-04-23),

Bionomics Inc. is a biopharmaceutical company focused on discovering and developing innovative therapeutic treatments for diseases with unmet medical needs. With a strong focus on developing personalized medicines, Bionomics aims to improve the lives of patients by delivering effective and targeted therapies. Through its cutting-edge research and strategic collaborations, Bionomics is committed to advancing the field of healthcare and making a meaningful impact on global healthcare challenges.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

64 Patents

#97 in San Diego, CA

#1,285 in California

#5,446 in US

#11,029 in the World

San Diego, CA, United States of America

Bionomics Inc.

Forward Citations = 189

91 inventors:

Bernard Luke Flynn (25 out of 27 patents)

Dharam Paul (16 out of 19 patents)

Jonathan Bayldon Baell (13 out of 28 patents)

4. Gabriel Kremmidiotis (13 out of 13 patents)

5. Andrew John Harvey (12 out of 23 patents)

Please report any incorrect information to support@idiyas.com

Loading…